Advertisement

Related Videos

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Jun
22
Today In Oncology
Addition of Mezigdomide to Carfilzomib/Dexamethasone in Relapsed or Refractory Multiple Myeloma
Ga-68–PSMA-11 PET-CT in Diagnosis of Prostate Cancer
Aumolertinib Plus Chemotherapy in EGFR-Mutated Advanced NSCLC
FDA Approves Capivasertib Plus Abiraterone and Prednisone for Metastatic Prostate Cancer
AGA Recommends Colonoscopy Over Alternative Colorectal Cancer Screening Methods
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo